ZN-c5

ZN-c5 is an orally available small molecule selective estrogen receptor degrader (SERD) developed for the treatment of estrogen receptor-positive (ER+) breast cancer. It acts by binding to the estrogen receptor and promoting its degradation, thereby inhibiting estrogen-driven tumor growth. Preclinical studies have shown that ZN-c5 is a potent antagonist and degradative agent of the estrogen receptor in both *in vitro* and *in vivo* models. The drug has demonstrated meaningful bone protectant activity in animal models, distinguishing it from other oral SERDs. ZN-c5 is being developed by Zeno Alpha (a subsidiary of Zentalis Pharmaceuticals), with Zentera Therapeutics also involved in development efforts[1][2][8]. Its primary clinical indication is ER+ breast cancer.